HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine supplements seized

This article was originally published in The Tan Sheet

Executive Summary

U.S. Marshals have seized $13,500 worth of dietary supplements containing ephedrine alkaloids that were located at ATF Fitness Products in Oakmont, Penn., FDA announces Feb. 25. The agency requested the products be confiscated following an investigation that "determined the products either contained prohibited ephedrine alkaloids or claimed to contain ephedrine or ephedrine alkaloids but did not," FDA says. The seized products include SciFit Procut lots 18822, 16312, 16918, 16834 and 19023, as well as Thermogen II lot 18981. FDA's rule prohibiting the sale of dietary supplements containing ephedrine alkaloids went into effect in April (1"The Tan Sheet" April 19, 2004, p. 12)...

You may also be interested in...



Firm Flouting Ephedra Ban Faces Product Seizure By U.S. Marshals

An FDA-prompted seizure of ephedra products could make it more likely Hi-Tech pharmaceuticals' suit against the FDA over the ephedra ban will go to court, according to the firm

Ephedra Ban Challengers Face Uphill Battle As Rule Goes Into Effect

Plaintiffs suing FDA to end the ephedra ban will have to assess the wisdom of continuing the suit after a federal judge has allowed the regulation to go into effect on schedule

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel